haematology oncology
GELF Criteria for Follicular Lymphoma
Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria identify high tumour burden in follicular lymphoma requiring treatment initiation. Any single criterion positive = high burden.
Score interpretation
Low Tumour Burden 0
No GELF criteria met — low tumour burden
→ Watch and wait strategy; no immediate treatment required
High Tumour Burden 1–8
≥1 GELF criterion met — high tumour burden
→ Treatment initiation indicated; refer to haematology for immunochemotherapy (e.g., R-CHOP or bendamustine-rituximab)
Interpretation bands for the GELF Criteria. Apply clinical judgement and local guidance.
References
- Brice P et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. J Clin Oncol. 1997;15(3):1110–1117.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Thiamine (IV/IM — Pabrinex) · Vitamin B1 (Thiamine) — deficiency treatment / Wernicke's encephalopathy prevention
- Obinutuzumab · Anti-CD20 Monoclonal Antibody — CLL / Follicular Lymphoma
- Idelalisib · PI3Kδ Inhibitor — CLL / Follicular Lymphoma
- Hydroxocobalamin (High-Dose — Cyanide Antidote) · Cyanide Antidote (Vitamin B12 Precursor at High Dose)
- Dextrose 10% IV · IV glucose solution (hypoglycaemia treatment)
- Glucose · Carbohydrate / hypoglycaemia treatment
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.